Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in HFpEF (PRESERVED-HF)
NCT03030235Phase 4Completed
- Sponsor
- Saint Luke's Health System
- Start
- Mar 2017
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin in heart failure with preserved ejection fraction (HFpEF), sponsored by Saint Luke's Health System. Started Mar 2017; status: completed.
02
Drugs
dapagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT03030235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03030235.